Lau K H, Tanimoto H, Baylink D J
Department of Medicine, Loma Linda University, California.
Endocrinology. 1988 Dec;123(6):2858-67. doi: 10.1210/endo-123-6-2858.
We recently proposed a hypothesis for the molecular mechanism of the osteogenic action of fluoride in which it stimulates osteoblast proliferation via the inhibition of an osteoblastic acid phosphatase-like phosphotyrosyl protein phosphatase activity. To test this hypothesis, we investigated whether orthovanadate, a known phosphotyrosyl protein phosphatase inhibitor, would mimic fluoride in the stimulation of bone cell proliferation and bone collagen synthesis in vitro. Orthovanadate inhibited the osteoblastic acid phosphatase activity and stimulated bone cell proliferation at the same low concentrations (i.e. 5-15 microM). At the mitogenic doses, orthovanadate also showed a dose-dependent increase in alkaline phosphatase (a marker of mature osteoblasts) in cultured calvarial cells and stimulated bone collagen synthesis, as measured by the incorporation of [3H]proline and the conversion into [3H] hydroxyproline in organ calvaria cultures. Therefore, orthovanadate stimulated bone formation by increasing the number of mature osteoblasts mediated via stimulation of cell proliferation and differentiation. Orthovanadate was dependent on the presence of a mitogen in cell medium for its mitogenic action in vitro and synergistically potentiated the mitogenic actions on osteoblasts of those growth factors, i.e. insulin, epidermal growth factor, insulin-like growth factor I, and skeletal growth factor, whose mitogenic action involved tyrosyl protein phosphorylation. However, the interaction between orthovanadate and basic fibroblast growth factor, a growth factor that does not appear to involve tyrosyl protein phosphorylation, on bone cell proliferation was additive. In summary, these data are consistent with the hypothesis that inhibition of the osteoblastic phosphotyrosyl protein phosphatases can prolong and/or potentiate the mitogenic actions of growth factors, and thereby stimulates cell proliferation.
我们最近提出了一个关于氟化物成骨作用分子机制的假说,即氟化物通过抑制成骨细胞酸性磷酸酶样磷酸酪氨酸蛋白磷酸酶活性来刺激成骨细胞增殖。为了验证这一假说,我们研究了正钒酸盐(一种已知的磷酸酪氨酸蛋白磷酸酶抑制剂)在体外是否能模拟氟化物刺激骨细胞增殖和骨胶原合成。正钒酸盐在相同的低浓度(即5 - 15微摩尔)下抑制成骨细胞酸性磷酸酶活性并刺激骨细胞增殖。在促有丝分裂剂量下,正钒酸盐还使培养的颅骨细胞中的碱性磷酸酶(成熟成骨细胞的标志物)呈剂量依赖性增加,并刺激骨胶原合成,这通过[3H]脯氨酸掺入以及在颅骨器官培养物中转化为[3H]羟脯氨酸来测定。因此,正钒酸盐通过增加成熟成骨细胞的数量来刺激骨形成,这是通过刺激细胞增殖和分化介导的。正钒酸盐在体外的促有丝分裂作用依赖于细胞培养基中存在促有丝分裂原,并协同增强了那些促有丝分裂作用涉及酪氨酸蛋白磷酸化的生长因子(即胰岛素、表皮生长因子、胰岛素样生长因子I和骨骼生长因子)对成骨细胞的促有丝分裂作用。然而,正钒酸盐与碱性成纤维细胞生长因子(一种似乎不涉及酪氨酸蛋白磷酸化的生长因子)在骨细胞增殖上的相互作用是相加的。总之,这些数据与以下假说一致,即抑制成骨细胞磷酸酪氨酸蛋白磷酸酶可以延长和/或增强生长因子的促有丝分裂作用,从而刺激细胞增殖。